Search Medical Condition
Please enter condition
Please choose location from dropdown

Shreveport, Louisiana Clinical Trials

A listing of Shreveport, Louisiana clinical trials actively recruiting patient volunteers.

RESULTS

Found (208) clinical trials

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants

This pivotal Phase 3 study will determine if MEDI8897 will prevent medically attended RSV-confirmed lower respiratory tract infections (LRTI) in healthy infants entering their first RSV season. The population to be enrolled is healthy late preterm and term infants born 35 weeks 0 days or greater gestational age (GA) who ...

Phase

1.48 miles

Learn More »

2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C

The clinical trial is to demonstrate that prodisc C SK and prodisc C Vivo are at least as safe and effective as a similar, currently marketed cervical disc prosthesis to treat symptomatic cervical disc disease (SCDD) in subjects at two contiguous levels from C3 to C7 who are unresponsive to ...

Phase N/A

1.48 miles

Learn More »

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

This study is a pivotal Phase 2/3 randomized, double-blind, palivizumab-controlled study to evaluate the safety, pharmacokinetics (PK), anti-drug antibody (ADA) response, and descriptive efficacy for MEDI8897 in high-risk infants eligible to receive palivizumab when entering their first or second RSV season (Season 1 or Season 2, respectively). Approximately 1,500 palivizumab-eligible ...

Phase

1.48 miles

Learn More »

Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function, reduce the risk of kidney failure, or reduce the risk of death due to kidney disease in participants with diabetic kidney disease (DKD).

Phase

1.48 miles

Learn More »

The standard of care is expected to remain unchanged during this run-in period. Patients whose proteinuria level remains >1 g/24-hours within 2 weeks of the end of the run-in period, who continue to have hematuria, and who meet blood pressure and eGFR criteria will be eligible to enroll in the ...

Phase

1.48 miles

Learn More »

For patients with autosomal dominant polycystic kidney disease (ADPKD) enrolled in this study, the objectives to assess bardoxolone methyl relative to placebo are as follows: Primary: - To assess the change from baseline in estimated glomerular filtration rate (eGFR) at Week 52 following a 4-week drug treatment withdrawal period. - ...

Phase N/A

1.48 miles

Learn More »

Open-label, 24-week, multicenter, exploratory cohort study of VCS - To assess the efficacy of voclosporin (VCS) in achieving complete or partial remission of proteinuria after 24 weeks of therapy in subjects with focal segmental glomerulosclerosis (FSGS). - To assess the safety and tolerability of VCS over 24 weeks in subjects ...

Phase

1.48 miles

Learn More »

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

This is a 2-part study, with Part A being the randomized, controlled portion of the study in patients with ABC (Acinetobacter baumannii-calcoaceticus Complex) hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or bacteremia. Part B is the single-group portion of the study and includes ABC infections that are resistant to ...

Phase

1.48 miles

Learn More »

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

This is a 52-week, multicenter, randomized, double-blind, parallel-group, flexible-dose study designed to evaluate the long-term safety and tolerability of SEP-363856 (50 to 100 mg/day) compared with quetiapine XR (400 to 800 mg/day) in clinically stable adult subjects with schizophrenia. This study is projected to randomize a least 300 subjects to ...

Phase

1.48 miles

Learn More »

A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain

The duration of treatment for each patient will be determined by the clinical need for parenteral opioid therapy. Eligible patients with moderate to severe pain caused by medical conditions or surgery, who require IV opioid therapy may be enrolled in this open label safety study. Patients will be treated with ...

Phase

1.48 miles

Learn More »